FDA Approves New mRNA Jab

The Food and Drug Administration (FDA) on Wednesday approved the first influenza jab in the United States to use mRNA technology.

The jab, called mFLUSIVA, was manufactured by COVID-19 jab maker Moderna.

Moderna received approval for the jab in all adults 50 years and older.

“The FDA approval of mFLUSIVA, our fourth approved product in the United States and the first mRNA-based flu vaccine, demonstrates the continued strength and versatility of our mRNA platform,” said Moderna CEO Stéphane Bancel.

“Flu remains a significant public health challenge, and mFLUSIVA provides an important new option for America’s seniors. This approval also reflects the ongoing potential of our mRNA platform to help address important public health challenges through continued scientific innovation. We are grateful to the clinical trial participants, investigators, regulators and Moderna teams whose contributions made this milestone possible,” he added.

Read Full Article Here